Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Advanced Cancer Therapeutics’ PFK-158 Featured in CEO/CFO MagazineAnnounces MD Anderson and UT Health Science Center San Antonio Added as Clinical Trial Sites
To read a full copy of the interview, please visit: https://ceocfointerviews.com/ In the article, Mr. Riggs announces that two new clinical trial sites have been added: MD Anderson Cancer Center in Houston, Texas and the University of Texas Health Science Center in San Antonio, Texas. The two new sites are expected to begin enrolling patients starting in January 1, 2015. PFK-158 human clinical trials began recruiting patients in May 2014 with the first clinical trial site located at the James Graham Brown Cancer Center, a part of KentuckyOne Health. Within weeks of opening the first clinical trial site, ACT was able to open the second clinical trial site, Georgetown University Medical Center in Washington, D.C., also in May 2014. According to Mr. Riggs, “We were pleased to partner with MD Anderson and UT Health Science Center in San Antonio to expand the number of clinical trial sites for PFK-158. PFK-158 is a first-in-man, novel anti-cancer drug that prevents tumor cells from using glucose as a fuel source for tumor survival, growth and metastasis and is currently in a Phase 1 clinical study in the US.” In November 2014, PFK-158 was chosen by Informa and Kantar Health as one of the “2014 Top 10 Most Interesting Oncology Projects to Watch.” PFK-158 is a small molecule that inactivates a novel cancer metabolism target never before examined in human clinical trials. Last spring, the U.S. Food and Drug Administration (FDA) approved Phase 1 dose escalation study that is evaluating the safety, tolerability and anti-tumor activity of PFK-158 in cancer patients with solid tumors such as prostate, lung, ovarian, melanoma, breast and pancreatic cancer. PFK-158 is the first 6-phosphofructo- CEO/CFO Magazineis a weekly online publication featuring in-depth interviews with many of today's top corporate executives. About Advanced Cancer Therapeutics (ACT): ACT is a privately held company dedicated to advancing novel therapeutics for the prevention and treatment of cancer. ACT has successfully established a unique and innovative business model with the University of Louisville’s James Graham Brown Cancer Center (Brown Cancer Center) whereby ACT is able to obtain exclusive worldwide licenses to novel cancer therapeutics discovered at Brown Cancer Center under preset business terms. ACT then fast-tracks these discoveries, including the selection process for partnership, commercialization and manufacture, to the pharmaceutical industry, and ultimately to the patients who need them. Led by Dr. Donald M. Miller, the Brown Cancer Center employs more than 50 scientists focused on the discovery and advancement of breakthrough cancer therapeutics for patients suffering from cancer. For more information, please visit www.advancedcancertherapeutics.com. End
Account Email Address Account Phone Number Disclaimer Report Abuse Page Updated Last on: Dec 15, 2014
|